Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
This model-building article (2020) argues that psychedelic-assisted therapy works to relax beliefs and increases acceptance via operant conditioning. This leas to less avoidance, more learning, and positive psychological outcomes.
Authors
- Lea Mertens
- Henrik Jungaberle
- Gerhard Gründer
Published
Abstract
The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled context of psychedelic therapy as applied in contemporary clinical research, psychedelic-induced belief relaxation can increase motivation for acceptance via operant conditioning, thus engendering episodes of relatively avoidance-free exposure to greatly intensified private events. Under these unique learning conditions, relaxed avoidance-related beliefs can be exposed to corrective information and become revised accordingly, which may explain long-term increases in acceptance and corresponding reductions in psychopathology. Open research questions and implications for clinical practice are discussed.
Research Summary of 'Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance'
Introduction
Recent early-phase clinical trials have reported that single or a few administrations of classic serotonergic psychedelics (most often psilocybin, but also LSD and ayahuasca) can produce substantial and sometimes sustained symptom reductions across a range of conditions, including depression, distress tied to life-threatening illness, obsessive–compulsive disorder and substance-use disorders. Previous work has suggested that a common pathway for these benefits is a shift from experiential avoidance to greater acceptance, but the psychological mechanisms by which psychedelic therapy might produce such change remain underspecified. Wolff and colleagues set out to clarify those mechanisms by developing a conceptual model from a cognitive–behavioural therapy (CBT) perspective, anchored in the relaxed-beliefs account of psychedelic action. The paper proposes that psychedelic-induced relaxation of high-level beliefs, when combined with typical therapeutic context factors, can increase motivation for acceptance via operant conditioning and create episodes of relatively avoidance-free exposure to highly intensified private events; under these learning conditions, avoidance-related beliefs may be revised and longer-term acceptance increased. The authors outline the model, relate it to existing CBT processes, review supporting empirical and qualitative observations, and discuss implications for research and clinical practice.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Topics
- Authors
- APA Citation
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020). Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00005
References (64)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Agin-Liebes, G. I., Malone, T., Yalch, M. M. et al. · Journal of Psychopharmacology (2020)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Show all 64 referencesShow fewer
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Kirchner, K. · Journal of Psychopharmacology (2014)
Kraehenmann, R., Nielson, E. M., May, D. G. et al. · Frontiers in Pharmacology (2018)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Mertens, L. J., Wall, M. B., Roseman, L. et al. · Journal of Psychopharmacology (2020)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Pink-Hashkes, S., Van Rooij, I., Kwisthout, J. · CogSci (2017)
Pahnke, W. N. · Psychedelic Review (1969)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)
Kaelen, M., Lorenz, R., Barrett, F. S. et al. · Biorxiv (2017)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Elices, M., Soler, J., Domínguez-Clavé, E. et al. · Frontiers in Pharmacology (2018)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Hendricks, P. S. · International Review of Psychiatry (2018)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Nielson, E. M., Guss, J. · Journal of Psychedelic Studies (2018)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Cited By (38)
Papers in Blossom that reference this study
Stellmacher, J., Schmidt, C., Aicher, H. D. et al. · Frontiers in Psychiatry (2026)
Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)
Cherniak, A. D., Granqvist, P., Mikulincer, M. et al. · Journal of Psychoactive Drugs (2026)
Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)
Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)
Zeifman, R. J., Spriggs, M. J., Kettner, H. et al. · Scientific Reports (2025)
Aday, J. S., Glynos, N., Baker, A. et al. · Preprints (2024)
McAlpine, R., Kamboj, S. K. · Scientific Reports (2024)
Krabbe, A., Sikka, P., Jylkkä, J. · Scientific Reports (2024)
Bonnelle, V., Feilding, A., Rosas, F. E. et al. · Journal of Psychopharmacology (2024)
Show all 38 papersShow fewer
Calder, A. E., Rausch, B., Liechti, M. E. et al. · Journal of Psychopharmacology (2024)
Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Pasquini, L., Simon, A. J., Gallen, C. L. et al. · Biorxiv (2024)
Elmer, T., Vannoy, T. K., Studerus, E. et al. · Scientific Reports (2024)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Zeifman, R. J., Wagner, A. C., Monson, C. M. et al. · Journal of Affective Disorders (2023)
Weiss, B., Wingert, A., Erritzoe, D. et al. · Scientific Reports (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Shnayder, S., Ameli, R., Sinaii, N. et al. · Journal of Affective Disorders (2023)
Breeksema, J. J., Niemeijer, A. R., Kuin, B. et al. · Frontiers in Psychiatry (2022)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Barba, T., Buehler, S., Kettner, H. et al. · BJPsych Open (2022)
Kaup, K. K., Vasser, M., Tulver, K. et al. · Frontiers in Psychiatry (2022)
Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)
Gandy, S. · Journal of Psychedelic Studies (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Strumila, R., Guillaume, S. · Pharmaceuticals (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)
Sumner, R. L., Chacko, E., Mcmillan, R. et al. · Journal of Psychopharmacology (2021)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Zeifman, R. J., Dos Santos, R. G., Sanches, R. F. et al. · Psychopharmacology (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.